The Joan Bisesi Fund for Head and Neck Oncology Research

The Joan Bisesi Fund for Head and Neck Oncology Research is both a culmination and a beginning — a culmination of Joan’s enduring dream and the beginning of a community-wide effort to help researchers overcome one of the most virulent forms of cancer.

As if to underscore the power of Joan’s visionary dream, when this fund was established in November 2001, it was with the commitment of reaching the basic level required for an endowment within five years. Remarkably, this initial goal was achieved in only six months.

With your continued support, Joan’s Fund can continue to raise awareness of head and neck cancer and support research that will save lives.

Goals of Joan's Fund

  • To save lives by increasing awareness of head and neck cancers. This year, more than 50,000 people in the United States will be diagnosed with a form of head and neck cancer, the most common being squamous cell carcinoma. If detected early, head and neck cancers are highly treatable and the cure rate is good.
  • To raise money to help find a cure. All money donated to Joan’s Fund supports head and neck oncology research at The James.

Each donation makes a difference. Even the smallest amount can be used as seed money to generate even larger grants from national research organizations.

Give By Mail

The OSUCCC – James
660 Ackerman Road, 6th Floor
PO Box 183112
Columbus, OH 43218-3112

Contact Us

OSUCCC – James Development Office

Phone

614-293-3752

Email

annualgiving@osumc.edu

By Mail

660 Ackerman Road, 6th Floor
PO Box 183112
Columbus, OH 43218-3112

Latest News

Nobel Prize Winner Carol Greider to Present Annual Block Lecture at Ohio State

Carol Greider, PhD, recipient of the 2009 Nobel Prize in Physiology or Medicine, will receive the 21st annual Herbert and Maxine Block Memorial Lectureship Award for Achievement in Cancer. The Block...

Read More

Researchers Detail Reasons for Ibrutinib Therapy Discontinuation in Chronic Lymphocytic Leukemia

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical...

Read More

Exciting Research in Lung Cancer Diagnosis and Treatments

This week on Toward a Cancer-Free World, we see how lung cancer treatments are now changing, thanks to exciting new research at The James.

Read More